Exact Mass: 368.23513219999995
Exact Mass Matches: 368.23513219999995
Found 500 metabolites which its exact mass value is equals to given mass value 368.23513219999995,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Perindopril
Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Perindopril may be used to treat mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease. C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09A - Ace inhibitors, plain > C09AA - Ace inhibitors, plain D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Perindopril (S-9490) is an orally available, long-acting angiotensin-converting enzyme (ACE) inhibitor. Perindopril inhibits inflammatory cell influx and intimal thickening, preserving elastin on the inside of the aorta. Perindopril effectively inhibits experimental abdominal aortic aneurysm (AAA) formation in a rat model and reduces pulmonary vasoconstriction in rats with pulmonary hypertension[1][2][3][4].
Propantheline
C23H30NO3+ (368.22255700000005)
Propantheline is only found in individuals that have used or taken this drug. It is a muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. [PubChem]The action of propantheline is achieved via a dual mechanism: (1) a specific anticholinergic effect (antimuscarinic) at the acetylcholine-receptor sites and (2) a direct effect upon smooth muscle (musculotropic). A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders > A03AB - Synthetic anticholinergics, quaternary ammonium compounds C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents
Cortol
Involved in C21-Steroid hormone metabolism. [HMDB] Involved in C21-Steroid hormone metabolism.
Prostaglandin G2
Prostaglandin G2 (PGG2) is synthesized from arachidonic acid on a cyclooxygenase (COX) metabolic pathway as a primary step; the COX biosynthesis of prostaglandin (PG) begins with the highly specific oxygenation of arachidonic acid in the 11R configuration and ends with a 15S oxygenation to form PGG2. The COX site activity that catalyzes the conversion of arachidonic acid to PGG2 is the target for nonsteroidal antiinflammatory drugs (NSAIDs). The peroxidase site activity catalyzes the two-electron reduction of the hydroperoxide bond of PGG2 to yield the corresponding alcohol prostaglandin H2 (PGH2). The formation of a phenoxyl radical on Tyr385 couples the activities of the two sites. The Tyr385 radical is produced via oxidation by compound I, an oxoferryl porphyrin -cation radical, which is generated by reaction of the hemin resting state with PGG2 or other hydroperoxides. The tyrosyl radical homolytically abstracts the 13proS hydrogen atom of arachidonic acid which initiates a radical cascade that ends with the stereoselective formation of PGG2. PGG2 then migrates from the cyclooxygenase (COX) site to the peroxidase (POX) site where it reacts with the hemin group to generate PGH2 and compound I. The heterolytic oxygen-oxygen bond cleavage is assisted by the conserved distal residues His207 and Gln203, mutation of which has been shown to severely impair enzyme activity. Compound I, upon reaction with Tyr385, gives compound II, which in turn is reduced to the hemin resting state by one-electron oxidation of reducing cosubstrates or undergoes reactions that result in enzyme self-inactivation. Prostaglandin endoperoxide H synthase (PGHS) 1 is a bifunctional membrane enzyme of the endoplasmic reticulum that converts arachidonic acid into prostaglandin H2 (PGH2), the precursor of all prostaglandins, thromboxanes, and prostacyclins. These lipid mediators are intricately involved in normal physiology, namely, in mitogenesis, fever generation, pain response, lymphocyte chemotaxis, fertility, and contradictory stimuli such as vasoconstriction and vasodilatation, as well as platelet aggregation and quiescence. PGHS is implicated in numerous pathologies, including inflammation, cancers of the colon, lung, and breast, Alzheimers disease, Parkinsons disease, and numerous cardiovascular diseases including atherosclerosis, thrombosis, myocardial infarction, and stroke. (PMID: 14594816, 16552393, 16411757). Prostaglandins are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. Prostaglandin G2 (PGG2) is synthesized from arachidonic acid on a cyclooxygenase (COX) metabolic pathway as a primary step; the COX biosynthesis of prostaglandin (PG) begins with the highly specific oxygenation of arachidonic acid in the 11R configuration and ends with a 15S oxygenation to form PGG2. D009676 - Noxae > D016877 - Oxidants > D010545 - Peroxides
6-Ketoprostaglandin E1
6-Ketoprostaglandin E1 (6-keto PGE1) is a biologically active and stable prostacyclin (PGI2) metabolite and a substrate for Adenylate cyclase type III. 6-keto PGE1 is a potent coronary vasodilator. 6-keto PGE1 could be elevated in plasma of patients with primary thrombocythaemia. 6-keto-PGE1 has approximately four times less potent antiplatelet activity than PGI2 on a molar basis in man. The cardiovascular and plasma renin activity (PRA) changes are less prominent for 6-keto-PGE1 than PGI2. Salt loading slightly increases urinary 6-keto PGE1. 6-keto-PGE1 elicits the same biological effects as PGI2 in human platelets and in rabbit aorta and mesenteric artery, being, however, less potent. 6-keto-PGE1 dose-dependently stimulates adenylate cyclase activity in membranes of human platelets and cultured myocytes from rabbit aorta and mesenteric artery. The extent of stimulation of the enzyme by 6-keto-PGE1 is the same as elicited by PGI2, while the apparent affinity is lower than that of prostacyclin, both in platelets and in vascular smooth muscle cells. At the level of platelet membranes, 6-keto-PGE1 interacts with the binding sites labelled by PGI2. However, in platelets as well as in mesenteric artery myocytes, 6-keto-PGE1 interacts with only one class of sites as demonstrated either by binding or by adenylate cyclase studies, whereas PGI2 in the same conditions recognizes two different classes. (PMID: 3186779, 3075239, 3472253, 3912001, 3881881, 6391491)Prostaglandins are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. 6-Ketoprostaglandin E1(6-keto PGE1) is a biologically active and stable prostacyclin (PGI2) metabolite and a substrate for Adenylate cyclase type III. 6-keto PGE1 is a potent coronary vasodilator. 6-keto PGE1 could be elevated in plasma of patients with primary thrombocythaemia. 6-keto-PGE1 has approximately four times less potent antiplatelet activity than PGI2 on a molar basis in man. The cardiovascular and plasma renin activity (PRA) changes are less prominent for 6-keto-PGE1 than PGI2. Salt loading slightly increases urinary 6-keto PGE1. D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
11-Dehydro-thromboxane B2
11-Dehydro-thromboxane B2, a stable thromboxane metabolite, is a full agonist of chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) in human eosinophils and basophils. Given its production in the allergic lung, antagonism of the 11-dehydro- thromboxane B2/CRTH2axis may be of therapeutic relevance. (PMID 14668348)Thromboxanes are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. 11-Dehydro-thromboxane B2, a stable thromboxane metabolite, is a full agonist of chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) in human eosinophils and basophils. Given its production in the allergic lung, antagonism of the 11-dehydro- thromboxane B2/CRTH2axis may be of therapeutic relevance. (PMID 14668348)
Carboprost Tromethamine
Carboprost Tromethamine is only found in individuals that have used or taken this drug. It is a nonsteroidal abortifacient agent that is effective in both the first and second trimesters of pregnancy. [PubChem]Carboprost is a synthetic prostaglandin. It binds the prostaglandin E2 receptor, causing myometrial contractions, casuing the induction of labour or the expulsion of the placenta. Prostaglandins occur naturally in the body and act at several sites in the body including the womb (uterus). They act on the muscles of the womb, causing them to contract. G - Genito urinary system and sex hormones > G02 - Other gynecologicals > G02A - Uterotonics > G02AD - Prostaglandins D012102 - Reproductive Control Agents > D000019 - Abortifacient Agents D012102 - Reproductive Control Agents > D010120 - Oxytocics C78568 - Prostaglandin Analogue
Cinncassiol D2
Cinncassiol D2 is found in herbs and spices. Cinncassiol D2 is a constituent of Cinnamomum cassia (Chinese cinnamon) Constituent of Cinnamomum cassia (Chinese cinnamon). Cinncassiol D2 is found in herbs and spices.
Cinncassiol D3
Cinncassiol D3 is found in herbs and spices. Cinncassiol D3 is a constituent of cinnamomi cortex, the dried bark of Cinnamomum cassia (Chinese cinnamon). Constituent of cinnamomi cortex, the dried bark of Cinnamomum cassia (Chinese cinnamon). Cinncassiol D3 is found in herbs and spices.
Cutamesine
C23H32N2O2 (368.24636519999996)
C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent D002491 - Central Nervous System Agents > D018697 - Nootropic Agents
Cinnarizine
Cinnarizine is an anti-histaminic drug which is mainly used for the control of vomiting due to motion sickness. Cinnarizine was first synthesized by Janssen Pharmaceutica in 1955. It acts by interfering with the signal transmission between vestibular apparatus of the inner ear and the vomiting centre of the hypothalamus. The disparity of signal processing between inner ear motion receptors and the visual senses is abolished, so that the confusion of brain whether the individual is moving or standing is reduced. Vomiting in motion sickness is actually a physiological compensatory mechanism of the brain to keep the individual from moving so that it can adjust to the signal perception. Cinnarizine could be also viewed as a nootropic drug because of its vasorelaxating abilities (due to calcium channel blockage), which happen mostly in brain. It is also effectively combined with other nootropics, primarily piracetam; in such combination each drug potentiate the other in boosting brain oxygen supply. N - Nervous system > N07 - Other nervous system drugs > N07C - Antivertigo preparations > N07CA - Antivertigo preparations D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators Cinnarizine is an antihistamine and a calcium channel blocker, promote cerebral blood flow, used to treat cerebral apoplexy, post-trauma cerebral symptoms, and cerebral arteriosclerosis.
Thromboxane B3
Thromboxane B3 (TXB3) is a prostanoid that is formed by the hydrolysis of TXA3, a product of dietary eicosapentaenoic acid transformed in humans. Prostanoids are a subclass of the lipid mediator group known as eicosanoids. They derive from C-20 polyunsaturated fatty acids, mainly dihomo-gamma-linoleic (20:3n-6), arachidonic (20:4n-6), and eicosapentaenoic (20:5n-3) acids, through the action of cyclooxygenases-1 and -2 (COX-1 and COX-2). The reaction product of COX is the unstable endoperoxide prostaglandin H (PGH) that is further transformed into the individual prostanoids by a series of specific prostanoid synthases. Prostanoids are local-acting mediators formed and inactivated within the same or neighbouring cells prior to their release into circulation as inactive metabolites (15-keto- and 13,14-dihydroketo metabolites). Non-enzymatic peroxidation of arachidonic acid and other fatty acids in vivo can result in prostaglandin-like substances isomeric to the COX-derived prostaglandins that are termed isoprostanes. Prostanoids take part in many physiological and pathophysiological processes in practically every organ, tissue and cell, including the vascular, renal, gastrointestinal and reproductive systems. Their activities are mediated through prostanoid-specific receptors and intracellular signalling pathways, whilst their biosynthesis and action are blocked by nonsteroidal antiinflammatory drugs (NSAID). Isoprostanes are considered to be reliable markers of oxidant stress status and have been linked to inflammation, ischaemia-reperfusion, diabetes, cardiovascular disease, reproductive disorders and diabetes. (PMID: 16986207, 2996649)Thromboxanes are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. Thromboxane B3 (TXB3) is a prostanoid that is formed by the hydrolysis of TXA3, a product of dietary eicosapentaenoic acid transformed in humans. Prostanoids are a subclass of the lipid mediator group known as eicosanoids. They derive from C-20 polyunsaturated fatty acids, mainly dihomo-gamma-linoleic (20:3n-6), arachidonic (20:4n-6), and eicosapentaenoic (20:5n-3) acids, through the action of cyclooxygenases-1 and -2 (COX-1 and COX-2). The reaction product of COX is the unstable endoperoxide prostaglandin H (PGH) that is further transformed into the individual prostanoids by a series of specific prostanoid synthases. Prostanoids are local-acting mediators formed and inactivated within the same or neighbouring cells prior to their release into circulation as inactive metabolites (15-keto- and 13,14-dihydroketo metabolites). Non-enzymatic peroxidation of arachidonic acid and other fatty acids in vivo can result in prostaglandin-like substances isomeric to the COX-derived prostaglandins that are termed isoprostanes. Prostanoids take part in many physiological and pathophysiological processes in practically every organ, tissue and cell, including the vascular, renal, gastrointestinal and reproductive systems. Their activities are mediated through prostanoid-specific receptors and intracellular signalling pathways, whilst their biosynthesis and action are blocked by nonsteroidal antiinflammatory drugs (NSAID). Isoprostanes are considered to be reliable markers of oxidant stress status and have been linked to inflammation, ischaemia-reperfusion, diabetes, cardiovascular disease, reproductive disorders and diabetes. (PMID: 16986207, 2996649)
19-Hydroxy-PGE2
19-Hydroxy-PGE2 is a derivative of PGE2. Both 19-Hydroxy-PGE1 and 19-hydroxy-PGE2 are formed from PGE1 and PGE2 by prostaglandin 19-hydroxylase, a cytochrome P-450 enzyme, in seminal vesicles (PMID: 3196735). 19-Hydroxy-PGE2 is a selective prostanoid EP2-receptor agonist; it doesnt stimulate FP-receptors, and is devoid of activity on thromboxane A2, prostaglandin D2 and prostacyclin sensitive receptors. 19-OH PGE2 is formed in large quantities from PGE2 in human seminal plasma. PGE2 is the most common and most biologically active of the mammalian prostaglandins. It has important effects in labour and also stimulates osteoblasts to release factors which stimulate bone resorption by osteoclasts (a type of bone cell that removes bone tissue by removing the bones mineralized matrix). (PMID: 16978535, 8248550, 817207). Dinoprostone is a naturally occurring prostaglandin E2 (PGE2) and the most common and most biologically active of the mammalian prostaglandins. It has important effects in labour and also stimulates osteoblasts to release factors which stimulate bone resorption by osteoclasts (a type of bone cell that removes bone tissue by removing the bones mineralized matrix). PGE2 has been shown to increase vasodilation and cAMP production, to enhance the effects of bradykinin and histamine, to induce uterine contractions and to activate platelet aggregation. PGE2 is also responsible for maintaining the open passageway of the fetal ductus arteriosus; decreasing T-cell proliferation and lymphocyte migration and activating the secretion of IL-1alpha and IL-2. PGE2 exhibits both pro- and anti-inflammatory effects, particularly on dendritic cells (DC). Depending on the nature of maturation signals, PGE2 has different and sometimes opposite effects on DC biology. PGE2 exerts an inhibitory action, reducing the maturation of DC and their ability to present antigen. PGE2 has also been shown to stimulate DC and promote IL-12 production when given in combination with TNF-alpha. PGE2 is an environmentally bioactive substance. Its action is prolonged and sustained by other factors especially IL-10. It modulates the activities of professional DC by acting on their differentiation, maturation and their ability to secrete cytokines. PGE2 is a potent inducer of IL-10 in bone marrow-derived DC (BM-DC), and PGE2-induced IL-10 is a key regulator of the BM-DC pro-inflammatory phenotype. (PMID: 16978535)Prostaglandins are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. 19-Hydroxy-PGE2 is a derivative of PGE2. Both 19-Hydroxy-PGE1 and 19-hydroxy-PGE2 are formed from PGE1 and PGE2 by prostaglandin 19-hydroxylase, a cytochrome P-450 enzyme, in seminal vesicles (PMID: 3196735). 19-Hydroxy-PGE2 is a selective prostanoid EP2-receptor agonist; it doesnt stimulate FP-receptors, and is devoid of activity on thromboxane A2, prostaglandin D2 and prostacyclin sensitive receptors. 19-OH PGE2 is formed in large quantities from PGE2 in human seminal plasma. PGE2 is the most common and most biologically active of the mammalian prostaglandins. It has important effects in labour and also stimulates osteoblasts to release factors which stimulate bone resorption by osteoclasts (a type of bone cell that removes bone tissue by removing the bones mineralized matrix). (PMID: 16978535, 8248550, 817207)
gamma-Eudesmol rhamnoside
gamma-Eudesmol rhamnoside is a constituent of fruits of Cananga odorata (ylang ylang). Constituent of fruits of Cananga odorata (ylang ylang)
20-Hydroxy-PGE2
20-hydroxy PGE2 is a product of cytochrome P450 metabolism of PGE2. ω-Oxidation at C-20 followed by beta-oxidation and the loss of up to 4 carbons from the lower side chain is a prominent metabolic pathway for PGE2. 20-hydroxy PGE2 is the putative first intermediate in this chain of chemical transformations. -- www.caymanchem.com. Dinoprostone is a naturally occurring prostaglandin E2 (PGE2) and the most common and most biologically active of the mammalian prostaglandins. It has important effects in labour and also stimulates osteoblasts to release factors which stimulate bone resorption by osteoclasts (a type of bone cell that removes bone tissue by removing the bones mineralized matrix). PGE2 has been shown to increase vasodilation and cAMP production, to enhance the effects of bradykinin and histamine, to induce uterine contractions and to activate platelet aggregation. PGE2 is also responsible for maintaining the open passageway of the fetal ductus arteriosus; decreasing T-cell proliferation and lymphocyte migration and activating the secretion of IL-1alpha and IL-2. PGE2 exhibits both pro- and anti-inflammatory effects, particularly on dendritic cells (DC). Depending on the nature of maturation signals, PGE2 has different and sometimes opposite effects on DC biology. PGE2 exerts an inhibitory action, reducing the maturation of DC and their ability to present antigen. PGE2 has also been shown to stimulate DC and promote IL-12 production when given in combination with TNF-alpha. PGE2 is an environmentally bioactive substance. Its action is prolonged and sustained by other factors especially IL-10. It modulates the activities of professional DC by acting on their differentiation, maturation and their ability to secrete cytokines. PGE2 is a potent inducer of IL-10 in bone marrow-derived DC (BM-DC), and PGE2-induced IL-10 is a key regulator of the BM-DC pro-inflammatory phenotype. (PMID: 16978535)Prostaglandins are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. 20-hydroxy PGE2 is a product of cytochrome P450 metabolism of PGE2.1 2 ω-Oxidation at C-20 followed by beta-oxidation and the loss of up to 4 carbons from the lower side chain is a prominent metabolic pathway for PGE2. 20-hydroxy PGE2 is the putative first intermediate in this chain of chemical transformations. -- www.caymanchem.com
6,15-Diketo,13,14-dihydro-PGF1a
6,15-diketo,13,14-dihydro-PGF1 alpha is a minor metabolite of prostacyclin (PGI2). Prostacyclin (PGI2) is one of the major vascular protectors against thrombosis and vasoconstriction, caused by thromboxane A(2). PGI2 inhibits platelet aggregation and vasoconstriction. PGI2 synthase (PGIS), a catalyst of PGI2 formation from prostaglandin H2, is widely distributed and predominantly found in vascular endothelial and smooth muscle cells. PGI2 plays an important cardioprotective role increasingly appreciated in recent years in light of adverse effects of COX-2 inhibitors in clinical trials. This cardioprotection is thought to be mediated, in part, by prostacyclin inhibition of platelet aggregation. Multiple lines of evidence suggest that prostacyclin additionally protects from cardiovascular disease by pleiotropic effects on vascular smooth muscle. PGI2 inhibits proliferation of cultured vascular SMCs by inhibiting cell cycle progression from G1 to S phase. Progression through G1 phase is regulated by the sequential activation of the G1 phase cyclin-dependent kinases (cdks). (PMID: 7000774, 6231483, 16303599, 16533160, 17073611, 17164138). 6,15-diketo,13,14-dihydro-PGF1 alpha is a minor metabolite of prostacyclin (PGI2). Prostacyclin (PGI2) is one of the major vascular protectors against thrombosis and vasoconstriction, caused by thromboxane A(2). PGI2 inhibits platelet aggregation and vasoconstriction. PGI2 synthase (PGIS), a catalyst of PGI2 formation from prostaglandin H2, is widely distributed and predominantly found in vascular endothelial and smooth muscle cells. PGI2 plays an important cardioprotective role increasingly appreciated in recent years in light of adverse effects of COX-2 inhibitors in clinical trials. This cardioprotection is thought to be mediated, in part, by prostacyclin inhibition of platelet aggregation. Multiple lines of evidence suggest that prostacyclin additionally protects from cardiovascular disease by pleiotropic effects on vascular smooth muscle. PGI2 inhibits proliferation of cultured vascular SMCs by inhibiting cell cycle progression from G1 to S phase. Progression through G1 phase is regulated by the sequential activation of the G1 phase cyclin-dependent kinases (cdks).
beta-Cortol
beta-Cortol is a normal androgen metabolite present in adults. It has been found in the urine of infants as well. Beta-Cortol is the 5b enantiomer of beta-allocortol. Beta-cortol levels are significantly higher in premenopausal women with leiomyomas than in age-matched healthy premenopausal control women. Uterine leiomyomas are tumors closely associated with estrogen levels and it has been noted that the development of leiomyomas depends on the condition of menstruation, perimenopause and pregnancy. (PMID: 14698830, 14616886, 14643447, 15635046, 14709852) [HMDB] beta-Cortol is a normal androgen metabolite present in adults. It has been found in the urine of infants as well. beta-Cortol is the 5beta enantiomer of beta-allocortol. beta-Cortol levels are significantly higher in premenopausal women with leiomyomas than in age-matched healthy premenopausal control women. Uterine leiomyomas are tumours closely associated with estrogen levels and it has been noted that the development of leiomyomas depends on the condition of menstruation, perimenopause, and pregnancy (PMID: 14698830, 14616886, 14643447, 15635046, 14709852).
5(6)-Epoxy Prostaglandin E1
Prostaglandins are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs) and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes) and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signaling pathways. [HMDB] Prostaglandins are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways.
20-COOH-10,11-dihydro-LTB4
20-COOH-10,11-dihydro-LTB4 is formed when leukotriene B4 (LTB4) is metabolized by beta-oxidation. LTB4 is the major metabolite in neutrophil polymorphonuclear leukocytes. Leukotrienes are metabolites of arachidonic acid derived from the action of 5-LO (5-lipoxygenase). The immediate product of 5-LO is LTA4 (leukotriene A4), which is enzymatically converted into either LTB4 (leukotriene B4) by LTA4 hydrolase or LTC4 (leukotriene C4) by LTC4 synthase. The regulation of leukotriene production occurs at various levels, including expression of 5-LO, translocation of 5-LO to the perinuclear region and phosphorylation to either enhance or inhibit the activity of 5-LO. Biologically active LTB4 is metabolized by w-oxidation carried out by specific cytochrome P450s (CYP4F) followed by beta-oxidation from the w-carboxy position and after CoA ester formation. (PMID: 8632343, 9667737). Leukotrienes are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. 20-COOH-10,11-dihydro-LTB4 is formed when leukotriene B4 (LTB4) is metabolized by beta-oxidation. LTB4 is the major metabolite in neutrophil polymorphonuclear leukocytes. Leukotrienes are metabolites of arachidonic acid derived from the action of 5-LO (5-lipoxygenase). The immediate product of 5-LO is LTA4 (leukotriene A4), which is enzymatically converted into either LTB4 (leukotriene B4) by LTA4 hydrolase or LTC4 (leukotriene C4) by LTC4 synthase. The regulation of leukotriene production occurs at various levels, including expression of 5-LO, translocation of 5-LO to the perinuclear region and phosphorylation to either enhance or inhibit the activity of 5-LO. Biologically active LTB4 is metabolized by w-oxidation carried out by specific cytochrome P450s (CYP4F) followed by beta-oxidation from the w-carboxy position and after CoA ester formation. (PMID: 8632343, 9667737)
20-dihydroxyleukotriene B4
20-dihydroxyleukotriene B4 is the metabolite of lipid omega-oxidation of leukotriene B4 (LTB4). LTB4 is the major metabolite in neutrophil polymorphonuclear leukocytes. Omega-oxidation is the major pathway for the catabolism of leukotriene B4 in human polymorphonuclear leukocytes. Leukotrienes are metabolites of arachidonic acid derived from the action of 5-LO (5-lipoxygenase). The immediate product of 5-LO is LTA4 (leukotriene A4), which is enzymatically converted into either LTB4 (leukotriene B4) by LTA4 hydrolase or LTC4 (leukotriene C4) by LTC4 synthase. The regulation of leukotriene production occurs at various levels, including expression of 5-LO, translocation of 5-LO to the perinuclear region, and phosphorylation to either enhance or inhibit the activity of 5-LO. Biologically active LTB4 is metabolized by omega-oxidation carried out by specific cytochrome P450s (CYP4F) followed by beta-oxidation from the omega-carboxy position and after CoA ester formation (PMID: 7649996, 17623009, 2853166, 6088485). Leukotrienes are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. 20-dihydroxyleukotriene B4 is the metabolite of lipid omega-oxidation of leukotriene B4 (LTB4). LTB4 is the major metabolite in neutrophil polymorphonuclear leukocytes. Omega-oxidation is the major pathway for the catabolism of leukotriene B4 in human polymorphonuclear leukocytes. Leukotrienes are metabolites of arachidonic acid derived from the action of 5-LO (5-lipoxygenase). The immediate product of 5-LO is LTA4 (leukotriene A4), which is enzymatically converted into either LTB4 (leukotriene B4) by LTA4 hydrolase or LTC4 (leukotriene C4) by LTC4 synthase. The regulation of leukotriene production occurs at various levels, including expression of 5-LO, translocation of 5-LO to the perinuclear region and phosphorylation to either enhance or inhibit the activity of 5-LO. Biologically active LTB4 is metabolized by w-oxidation carried out by specific cytochrome P450s (CYP4F) followed by beta-oxidation from the w-carboxy position and after CoA ester formation. (PMID: 7649996, 17623009, 2853166, 6088485)
19-hydroxyprostaglandin H2(1-)
19-hydroxyprostaglandin H2(1-) is considered to be practically insoluble (in water) and acidic
20-hydroxylipoxin A4
20-hydroxylipoxin A4 is considered to be practically insoluble (in water) and acidic
(E)-7-[4-Hydroxy-2-[(E)-3-hydroxyoct-1-enyl]-6-oxooxan-3-yl]hept-5-enoic acid
19-Hydroxyprostaglandin E2
Arginyl-prolyl-proline
(R-(R*,S*))-3-(3-Cyclohexyl-3-hydroxypropyl)-2,5-dioxoimidazolidine-4-heptanoic acid
Cutamesine
C23H32N2O2 (368.24636519999996)
C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent D002491 - Central Nervous System Agents > D018697 - Nootropic Agents
Menoctone
C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C277 - Antiprotozoal Agent
Prostaglandin F2alpha methyl ester
2'-Epi-Perindopril, (2'R)-
MG(18:2(10E,12Z)+=O(9)/0:0/0:0)
MG(18:2(10E,12Z)+=O(9)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(18:2(9Z,11E)+=O(13)/0:0/0:0)
MG(18:2(9Z,11E)+=O(13)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(18:3(10,12,15)-OH(9)/0:0/0:0)
MG(18:3(10,12,15)-OH(9)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(18:3(9,11,15)-OH(13)/0:0/0:0)
MG(18:3(9,11,15)-OH(13)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/18:2(10E,12Z)+=O(9)/0:0)
MG(0:0/18:2(10E,12Z)+=O(9)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/18:2(9Z,11E)+=O(13)/0:0)
MG(0:0/18:2(9Z,11E)+=O(13)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/18:3(10,12,15)-OH(9)/0:0)
MG(0:0/18:3(10,12,15)-OH(9)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/18:3(9,11,15)-OH(13)/0:0)
MG(0:0/18:3(9,11,15)-OH(13)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
C7FEJ7QWQE
Rhodojaponin III is a natural product found in Rhododendron simsii, Rhododendron catawbiense, and other organisms with data available. Rhodojaponin III is a diterpenoid from the leaves of Rhododendron molle with anti-inflammatory activity[1]. Rhodojaponin III is a diterpenoid from the leaves of Rhododendron molle with anti-inflammatory activity[1].
ent-6alpha,7alpha,16beta,17-Tetrahydroxykauranoic acid
[1R-(1alpha,2alpha,4aalpha,5alpha,8abeta)]-1,2,3,4,4a,5,6,8a-Octahydro-5-hydroxy-4a,8-dimethyl-2-(1-methylethyl)-1-naphthalenyl ester 3-phenyl-2-propenoic acid
[1R-[1alpha,4alpha,4aalpha,5alpha(E),6alpha,8abeta]]-Decahydro-4,8a-dimethyl-6-(1-methylethyl)-1,4-epoxynaphthalen-5-yl ester 3-phenyl-2-propenoic acid
Tomentogenin|Tomentogenin (5alpha-Dihydro-utendin)
(1beta,4alpha,5beta,6alpha,7alpha,10alpha)-10-Aromadendranol
tetrahydro-2-(14-hydroxypentadecyl)-4-methylene-5-oxo-3-furancarboxylic acid
methyl-2alpha,3alpha,9beta-trihydroxy-9-epi-labd-13(E)-en-15-oate
(-)-dihydropertusaric acid|(-)589-Pertusarinic acid|(2S,3S,4S)-2,3,4,5-tetrahydro-4-methyl-5-oxo-2-(14-oxopentadecyl)furan-3-carboxylic acid|(3S,4S,5S)-4-carboxy-3-methyl-2-oxo-5-(14-oxopentadecyl)tetrahydrofuran
3-hydroxy-2-(hydroxymethyl)-4-(14-methylpentadecanoyl)-2H-furan-5-one
6beta-(Cinnamoyloxy)eudesman-14-al|6beta-cinnamoyleudesman-15-al
agallochin M|methyl ent-13-epi-8,13-epoxy-4,6alpha-dihydroxy-3,4-secolabd-14-en-3-oate
2,3-epoxy-5beta,6cbeta;,10alpha,13beta,16alpha-pentahydroxy-grayanane|craiobiotoxin IX
(-)-PGE1 methyl ester|(-)-prostaglandin E1 methyl ester|methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxy-1-octenyl]-5-oxocyclopentyl]heptanoate|Methyl prostaglandin E1|PGE1 methyl ester|prostaglandin E1 methyl ester
Rhodojaponin III
Rhodojaponin III is a diterpenoid from the leaves of Rhododendron molle with anti-inflammatory activity[1]. Rhodojaponin III is a diterpenoid from the leaves of Rhododendron molle with anti-inflammatory activity[1].
(2S)-1-O-(9-oxo-10(E),12(E)-octadecadienoyl) glycerol
rhodomollein F,,2,3,6,14,16-pentahydroxyl-5,9-epoxy grayanotoxane
(4S,5S,7R,10S)-Eudesm-11-en-4-ol beta-D-fucopyranoside
(5S,6E,8Z,11Z,13E,15S)-5,15-Dihydroperoxy-6,8,11,13-eicosatetraenoic acid
17-Methoxy-1-propionyl-aspidospermidin|17-methoxy-1-propionyl-aspidospermidine|Palosine
C23H32N2O2 (368.24636519999996)
Perindopril
C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09A - Ace inhibitors, plain > C09AA - Ace inhibitors, plain D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents CONFIDENCE standard compound; EAWAG_UCHEM_ID 3026 Perindopril (S-9490) is an orally available, long-acting angiotensin-converting enzyme (ACE) inhibitor. Perindopril inhibits inflammatory cell influx and intimal thickening, preserving elastin on the inside of the aorta. Perindopril effectively inhibits experimental abdominal aortic aneurysm (AAA) formation in a rat model and reduces pulmonary vasoconstriction in rats with pulmonary hypertension[1][2][3][4].
C20H32O6_(2E)-2-(1,2-Dihydroxyethyl)-4-[(1R,4aS,5R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenedecahydro-1-naphthalenyl]-2-butenoic acid
Thromboxane B3
A member of the class of thromboxanes B that is (5Z,13E,17Z)-thromboxa-5,13,17-trien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. CONFIDENCE standard compound; NATIVE_RUN_ID STD_neg_MSMS_1min0072.mzML; PROCESSING averaging of repeated ion fragments at 20.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001323.mzML; PROCESSING averaging of repeated ion fragments at 20.0 NCE within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001323.mzML; PROCESSING averaging of repeated ion fragments at 30.0 NCE within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001323.mzML; PROCESSING averaging of repeated ion fragments at 40.0 NCE within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001323.mzML; PROCESSING averaging of repeated ion fragments at 20.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001323.mzML; PROCESSING averaging of repeated ion fragments at 30.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID STD_neg_MSMS_1min0072.mzML; PROCESSING averaging of repeated ion fragments at 30.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID STD_neg_MSMS_1min0072.mzML; PROCESSING averaging of repeated ion fragments at 10.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001323.mzML; PROCESSING averaging of repeated ion fragments at 10.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ]
cinnarizine
N - Nervous system > N07 - Other nervous system drugs > N07C - Antivertigo preparations > N07CA - Antivertigo preparations D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators Cinnarizine is an antihistamine and a calcium channel blocker, promote cerebral blood flow, used to treat cerebral apoplexy, post-trauma cerebral symptoms, and cerebral arteriosclerosis.
5,12-dihydroperoxy-6,8,10,14-eicosatetraenoic acid
5,15-dihydroperoxy-6,8,11,13-eicosatetraenoic acid
8,15-dihydroperoxy-5,9,11,13-eicosatetraenoic acid
6,15-Diketo-13,14-dihydro-PGF1a
20-hydroxy-PGE2
Eganoprost
Carboprost
G - Genito urinary system and sex hormones > G02 - Other gynecologicals > G02A - Uterotonics > G02AD - Prostaglandins D012102 - Reproductive Control Agents > D000019 - Abortifacient Agents D012102 - Reproductive Control Agents > D010120 - Oxytocics C78568 - Prostaglandin Analogue
5,15-diHPETE
D009676 - Noxae > D016877 - Oxidants > D010545 - Peroxides
8,15-diHPETE
D009676 - Noxae > D016877 - Oxidants > D010545 - Peroxides
gamma-Eudesmol rhamnoside
Prostaglandin G2
D009676 - Noxae > D016877 - Oxidants > D010545 - Peroxides
FA 20:4;O4
D009676 - Noxae > D016877 - Oxidants > D010545 - Peroxides
[3aS-(3aa,4a,5b,6aa)]-4-[[[(tert-Butyl)dimethylsilyl]oxy]methyl]-5-[(tetrahydro-2H-pyran-2-yl)oxy]hexahydro-2(1H)-pentalenone
1-(tert-butyl)-3-(2,6-diisopropyl-4-phenoxyphenyl)urea
C23H32N2O2 (368.24636519999996)
4-Fluoro-Phenyl-4-Trans-PentylcyclohexylBenzoate
C24H29FO2 (368.21514659999997)
1-[(TRANS,TRANS)-4-PROPYL[1,1-BICYCLOHEXYL]-4-YL]-4-(TRIFLUOROMETHOXY)BENZENE
Poly(1,6-hexanediol/neopentyl glycol-alt-adipic acid)
(16S,20S)-Pregnan-3beta,5alpha,6beta,16,20-pentaol
(R-(R*,S*))-3-(3-Cyclohexyl-3-hydroxypropyl)-2,5-dioxoimidazolidine-4-heptanoic acid
20-Hydroxylipoxin B4
A member of the class of lipoxins that is lipoxin B4 carrying an additional hydroxy substituent at position 20.
(S-(R*,S*))-3-(3-Cyclohexyl-3-hydroxypropyl)-2,5-dioxoimidazolidine-4-heptanoic acid
6-(Cyclohexylamino)-9-[2-(4-methylpiperazin-1-YL)-ethyl]-9H-purine-2-carbonitrile
N-[(1s)-1-{1-[(1r,3e)-1-Acetylpent-3-En-1-Yl]-1h-1,2,3-Triazol-4-Yl}-1,2-Dimethylpropyl]benzamide
Menoctone
C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C277 - Antiprotozoal Agent
(5Z,13E,15S)-11alpha,15,19-trihydroxy-6,9alpha-epoxyprosta-5,13-dien-1-oic acid
(3R,17R)-17-(1,2-dihydroxyethyl)-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthrene-3,11,17-triol
Prost-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, (11alpha,13E)-(+-)-
20-hydroxylipoxin A4
A member of the class of lipoxins that is lipoxin A4 carrying an additional hydroxy substituent at position 20.
11-Dehydro-thromboxane B2
A thromboxane obtained by formal oxidation of the hemiacetal hydroxy function of thromboxane B2.
[(2S)-2,3-dihydroxypropyl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate
[(2S)-2,3-dihydroxypropyl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate
1,3-dihydroxypropan-2-yl (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate
1,3-dihydroxypropan-2-yl (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate
(E)-7-[6-[(E)-3,7-dihydroxyoct-1-enyl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]hept-5-enoic acid
[3-Carboxy-2-[3-(3-methyl-5-pentylfuran-2-yl)propanoyloxy]propyl]-trimethylazanium
C20H34NO5+ (368.24368540000006)
19-Hydroxyprostaglandin H2
A prostaglandin H that consists of prostaglandin H2 bearing an additional hydroxy substituent at position 19.
(E)-4-[(1R,4aS,5R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]-2-(1,2-dihydroxyethyl)but-2-enoic acid
Hinesol beta-D-fucopyranoside, (rel)-
A natural product found in Carthamus oxyacantha.
N-[3-(diethylamino)propyl]-1,5-dimethyl-4-oxo-2-pyrrolo[3,2-c]quinolinecarboxamide
5-(Hydroxymethyl)-3-(1-oxohexadecyl)oxolane-2,4-dione
1-[3-(2-Hydroxypropoxy)-2,2-bis(2-hydroxypropoxymethyl)propoxy]propan-2-ol
2-[(3R,6aR,8R,10aR)-1-[cyclopentyl(oxo)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide
2-[(3R,6aS,8R,10aS)-1-(cyclopentanecarbonyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide
N-(cyclobutylmethyl)-N-[[(2S,3R,4S)-3-[4-(1-cyclopentenyl)phenyl]-4-(hydroxymethyl)-2-azetidinyl]methyl]acetamide
C23H32N2O2 (368.24636519999996)
2-[(3S,6aS,8R,10aS)-1-[cyclopentyl(oxo)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide
N-(cyclobutylmethyl)-N-[[(2R,3S,4R)-3-[4-(1-cyclopentenyl)phenyl]-4-(hydroxymethyl)-2-azetidinyl]methyl]acetamide
C23H32N2O2 (368.24636519999996)
2-[(3R,6aS,8S,10aS)-1-[cyclopentyl(oxo)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide
2-[(3S,6aS,8S,10aS)-1-[cyclopentyl(oxo)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide
2-[(3S,6aR,8S,10aR)-1-[cyclopentyl(oxo)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide
2-[(3R,6aR,8S,10aR)-1-[cyclopentyl(oxo)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide
1-[[(2S,3R,4S)-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-3-propyl-1-(3-pyridinylmethyl)urea
(5Z,13E,15S)-9alpha,11alpha-epoxy-15,18-dihydroxythromboxa-5,13-dien-1-oic acid
(5Z,13E,15S)-9alpha,11alpha-epoxy-15,19-dihydroxythromboxa-5,13-dien-1-oic acid
(5S,6Z,8E,10E,12R,14Z)-5,12,20,20-tetrahydroxyicosa-6,8,10,14-tetraenoic acid
(5Z,8Z,10E,12E,14R,15S)-14,15-bis(hydroperoxy)icosa-5,8,10,12-tetraenoic acid
(5S,6R,7E,9E,11Z,13E,15S)-15-hydroperoxy-5,6-dihydroxyicosa-7,9,11,13-tetraenoic acid
3-Methyl-6-nonyl-6-(tetrahydro-2H-pyran-2-yloxymethyl)tetrahydro-2H-pyran-2,4-dione
(1-acetyloxy-3-hydroxypropan-2-yl) (9Z,12Z)-hexadeca-9,12-dienoate
(2S)-2-[1-Azido-4-[(tetrahydro-2H-pyran-2-yl)oxy]butyl]-1-pyrrolidinecarboxylic acid tert-butyl ester
C18H32N4O4 (368.24234320000005)
(2R)-2-[(14S)-14-hydroxypentadecyl]-4-methylidene-5-oxooxolane-3-carboxylic acid
(2R,3aS,7aS)-1-[(2S)-2-[(1-ethoxy-1-oxopentan-2-yl)amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid
propantheline
C23H30NO3+ (368.22255700000005)
A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders > A03AB - Synthetic anticholinergics, quaternary ammonium compounds C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents
6-Oxoprostaglandin e1
A prostaglandin E that is prostaglandin E1 bearing a keto substituent at the 6-position. D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
(1R,2S,4S,6R,10S,11S,13S,14S)-11-(1-hydroxypropan-2-yl)-3,7,10-trimethyl-15-oxapentacyclo[7.5.1.02,6.07,13.010,14]pentadecane-4,6,9,14-tetrol
(1R,2R,3S,6R,10S,11S,13S,14S)-11-(1-Hydroxypropan-2-yl)-3,7,10-trimethyl-15-oxapentacyclo[7.5.1.02,6.07,13.010,14]pentadecane-3,6,9,14-tetrol
7-[3-(3-cyclohexyl-3-hydroxypropyl)-2,5-dioxoimidazolidin-4-yl]heptanoic acid
6,15-diketo,13,14-dihydroprostaglandin F1alpha
A prostaglandin Falpha that is prostaglandin F1alpha bearing keto substituents at positions 6 and 15.
8(S),15(S)-DiHPETE
An icosanoid that is (5Z,9E,11Z,13E)-icosatetraenoic acid carrying two hydroperoxy substituents at positions 8 and 15 (the 8S,15S-stereoisomer).
(5S,15S)-dihydroperoxy-(6E,8Z,11Z,13E)-icosatetraenoic acid
A bis(hydroperoxy)icosatetraenoic acid that is (6E,8Z,11Z,13E)-icosatetraenoic acid in which the two hydroperoxy groups are located at positions 5S and 15S.
14(R),15(S)-DiHPETE
A bis(hydroperoxy)icosatetraenoic acid that is (5Z,8Z,10E,12E)-icosatetraenoic acid carrying two hydroperoxy substituents at positions 14 and 15 (the 14R,15S-stereoisomer).
(5S,6R)-dihydroxy-(15S)-hydroperoxy-(7E,9E,11Z,13E)-icosatetraenoic acid
A hydroperoxy(hydroxy)icosatetraenoic acid that is (7E,9E,11Z,13E)-icosatetraenoic acid carrying 2 hydroxy substituents at positions 5S and 6R as well as a hydroperoxy substituent at position 15S.
19-hydroxyprostaglandin I2
A prostaglandin I that consists of prostaglandin I1 carrying an additional hydroxy substituent at position 19.
19-hydroxythromboxane A2
A thromboxane A that is thromboxane A2 carrying an additional hydroxy substituent at position 19.
18-hydroxythromboxane A2
A thromboxane A that is thromboxane A2 carrying an additional hydroxy substituent at position 18.
DG(18:2)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
IDF-11774
C23H32N2O2 (368.24636519999996)
IDF-11774 is a novel hypoxia-inducible factor α (HIFα)-1 inhibitor with an IC50 of 3.65?μM.
(1s,3r,4r,6r,7s,8r,10s,13r,14r,16r)-5,5,14-trimethyl-9-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecane-3,4,6,7,14,16-hexol
(1s,3r,4r,8s,9r,10r,13r,14r,16r)-3,4,9,14,16-pentahydroxy-5,5,9,14-tetramethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecan-6-one
(2r)-2,3-dihydroxypropyl (10e,12z)-9-oxooctadeca-10,12-dienoate
4-(acetyloxy)-5-hydroxy-5-undecanoylcyclopent-2-en-1-yl acetate
4-hydroxy-7-isopropyl-1,4a-dimethyl-2,3,4,5,8,8a-hexahydronaphthalen-1-yl 3-phenylprop-2-enoate
(1r,2s,4s,4as,5s,5'r,5''s,8as)-4,5''-dihydroxy-5-(hydroxymethyl)-2,5,8a-trimethyl-hexahydrodispiro[naphthalene-1,2':5',3''-bis(oxolane)]-3-one
(1s,3s,4r,6r,7s,8r,10s,13r,14r,16r)-5,5,14-trimethyl-9-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecane-3,4,6,7,14,16-hexol
(2r,3s)-2-[(14r)-14-hydroxypentadecyl]-4-methylidene-5-oxooxolane-3-carboxylic acid
(2e,4r)-4-[(1r,3as,3bs,9ar,9bs,11ar)-9a,11a-dimethyl-7-oxo-1h,2h,3h,3ah,3bh,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]pent-2-enoic acid
(2s)-2,3-dihydroxypropyl 9-oxooctadeca-10,12-dienoate
5-hydroxy-2-isopropyl-8,8a-dimethyl-2,3,5,6,7,8-hexahydro-1h-naphthalen-1-yl 3-phenylprop-2-enoate
(1r,2s,3s,5s,6r,7r,8s,9r,10s,11r,18r)-6,12,12-trimethyl-17-oxapentacyclo[7.6.2.1⁵,⁸.0¹,¹¹.0²,⁸]octadecane-3,7,9,10,18-pentol
4-methoxy-6-(2,4,8-trihydroxy-3,7,9-trimethylundeca-5,9-dien-1-yl)-5,6-dihydropyran-2-one
(3r,4r,8s,9r,10r,14r,16s)-3,4,9,14,16-pentahydroxy-5,5,9,14-tetramethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecan-6-one
(1r)-3-[(3e)-5-(2h-chromen-7-yloxy)-3-methylpent-3-en-1-yl]-2,2,4-trimethylcyclohex-3-en-1-ol
(1r,4s,6s,10r,13s,14r,17s)-10-hydroperoxy-13-hydroxy-4,13,17-trimethyl-9-methylidene-5,15-dioxatricyclo[12.3.1.0⁴,⁶]octadecan-16-one
(1r,3r,4r,6r,7r,8s,9r,10r,13s,16r)-5,5,9-trimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecane-3,4,6,7,9,16-hexol
(1r,3s,4r,7s,11s,12r)-3,4,7,11-tetrahydroxy-4,12-dimethyl-8,15-dimethylidene-13-oxabicyclo[10.3.2]heptadecan-14-one
(1r,2r,3r,4as,5s,5'r,5''r,8as)-3,5''-dihydroxy-5-(hydroxymethyl)-2,5,8a-trimethyl-hexahydrodispiro[naphthalene-1,2':5',3''-bis(oxolane)]-4-one
(2s,3s)-2-[(14r)-14-hydroxypentadecyl]-4-methylidene-5-oxooxolane-3-carboxylic acid
(1s,3s,4r,6s,7s,8s,10s,13r,14s,16r)-5,5,14-trimethyl-9-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecane-3,4,6,7,14,16-hexol
(1r,4s,6s,10s,13s,14r,17s)-10-hydroperoxy-13-hydroxy-4,13,17-trimethyl-9-methylidene-5,15-dioxatricyclo[12.3.1.0⁴,⁶]octadecan-16-one
11-isopropyl-3,7,10-trimethyl-15-oxapentacyclo[7.5.1.0²,⁶.0⁷,¹³.0¹⁰,¹⁴]pentadecane-6,9,11,13,14-pentol
2-[5-(carboxymethyl)-2,5,8a-trimethyl-2-(oxiran-2-yl)-hexahydro-1-benzopyran-6-yl]-2-methylpropanoic acid
1-[2,4-dihydroxy-6-(10-phenyldecyl)phenyl]ethanone
(1r,2s,5e,10r,11r,18s,21r)-5,15,17,17-tetramethyl-9-methylidene-12,16-dioxapentacyclo[12.6.1.0¹,¹¹.0²,¹⁰.0¹⁸,²¹]henicosa-5,14-dien-13-one
4-hydroxy-5-(hydroxymethyl)-3-(14-methylpentadecanoyl)-5h-furan-2-one
3-[5-(2h-chromen-7-yloxy)-3-methylpent-3-en-1-yl]-2,2,4-trimethylcyclohex-3-en-1-ol
(1r,2s,4s,4as,5s,5'r,5''r,8as)-4,5''-dihydroxy-5-(hydroxymethyl)-2,5,8a-trimethyl-hexahydrodispiro[naphthalene-1,2':5',3''-bis(oxolane)]-3-one
(2s,3r,4s,5r,6r)-2-({2-[(2r,4as)-4a,8-dimethyl-2,3,4,5,6,7-hexahydro-1h-naphthalen-2-yl]propan-2-yl}oxy)-6-methyloxane-3,4,5-triol
3-ethenyl-1-(2-hydroxy-6-methylphenyl)-3,7,11-trimethyldodeca-6,10-diene-1,5-dione
(1r,2r,3r,4as,5s,5'r,5''s,8as)-3,5''-dihydroxy-5-(hydroxymethyl)-2,5,8a-trimethyl-hexahydrodispiro[naphthalene-1,2':5',3''-bis(oxolane)]-4-one
(1r,2r,3s,4s,5s,9s,10s,13r,14s)-2,3,14-trihydroxy-14-(hydroxymethyl)-5,9-dimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylic acid
(1r,3r,4r,6s,7r,8r,9s,10s,13s,16r)-5,5,9-trimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecane-3,4,6,7,9,16-hexol
(5z)-7-[(1s,4r,5r,6r)-6-[(1e,3s)-3-hydroperoxyoct-1-en-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]hept-5-enoic acid
(1r,2s,4ar,5r,8as)-5-hydroxy-2-isopropyl-4a-methyl-8-methylidene-octahydronaphthalen-1-yl (2e)-3-phenylprop-2-enoate
8a-hydroxy-1-isopropyl-3a,6-dimethyl-1,2,3,4,7,8-hexahydroazulen-4-yl 3-phenylprop-2-enoate
(1r,2s,5r,8s,8ar)-5-hydroxy-2-isopropyl-8,8a-dimethyl-2,3,5,6,7,8-hexahydro-1h-naphthalen-1-yl (2e)-3-phenylprop-2-enoate
(1r,2s,5s,6s,9r,12s,13s)-n,6,13-trimethyl-16-oxo-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-diene-7-carboximidic acid
C23H32N2O2 (368.24636519999996)
{6-hydroxy-7-methyl-1-[(3-methylbutanoyl)oxy]-1h,4ah,5h,6h,7h,7ah-cyclopenta[c]pyran-4-yl}methyl 3-methylbutanoate
15-epi-leopersin o
{"Ingredient_id": "HBIN001675","Ingredient_name": "15-epi-leopersin o","Alias": "NA","Ingredient_formula": "C20H32O6","Ingredient_Smile": "CC1C(C(=O)C2C(CCCC2(C13CCC4(O3)CC(OC4)O)C)(C)CO)O","Ingredient_weight": "368.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "6948","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "15834304","DrugBank_id": "NA"}
15-epi-leopersin q
{"Ingredient_id": "HBIN001676","Ingredient_name": "15-epi-leopersin q","Alias": "NA","Ingredient_formula": "C20H32O6","Ingredient_Smile": "CC1C(=O)C(C2C(CCCC2(C13CCC4(O3)CC(OC4)O)C)(C)CO)O","Ingredient_weight": "368.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "6949","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "15834667","DrugBank_id": "NA"}
adenostemmoic acid c
{"Ingredient_id": "HBIN014705","Ingredient_name": "adenostemmoic acid c","Alias": "NA","Ingredient_formula": "C20H32O6","Ingredient_Smile": "CC12CCCC(C1CCC34C2C(CC(C3)C(C4O)(CO)O)O)(C)C(=O)O","Ingredient_weight": "368.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "24816","TCMSP_id": "NA","TCM_ID_id": "7152","PubChem_id": "23260137","DrugBank_id": "NA"}
agallochin m
{"Ingredient_id": "HBIN014811","Ingredient_name": "agallochin m","Alias": "NA","Ingredient_formula": "C21H36O5","Ingredient_Smile": "CC1(CCC2C(O1)(CC(C(C2(C)CCC(=O)OC)C(C)(C)O)O)C)C=C","Ingredient_weight": "368.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "693","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "101232173","DrugBank_id": "NA"}
alpha-bisabolol beta-d-fucopyranoside
{"Ingredient_id": "HBIN015411","Ingredient_name": "alpha-bisabolol beta-d-fucopyranoside ","Alias": "NA","Ingredient_formula": "C21H36O5","Ingredient_Smile": "CC1C(C(C(C(O1)OC(C)(CCC=C(C)C)C2CCC(=CC2)C)O)O)O","Ingredient_weight": "368.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "19480","PubChem_id": "102286643","DrugBank_id": "NA"}
(1r,3r,4r,6r,7r,8s,9r,10r,13s,16s)-5,5,9,14-tetramethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadec-14-ene-3,4,6,7,9,16-hexol
5-hydroxy-2-isopropyl-4a-methyl-8-methylidene-octahydronaphthalen-1-yl 3-phenylprop-2-enoate
(2s,3r,4r,5r,6s)-2-({2-[(2r,4ar)-4a,8-dimethyl-2,3,4,5,6,7-hexahydro-1h-naphthalen-2-yl]propan-2-yl}oxy)-6-methyloxane-3,4,5-triol
(1s,4as,5r,6s,8ar)-5-[(2h-chromen-7-yloxy)methyl]-1,5,6,8a-tetramethyl-hexahydro-1h-naphthalen-2-one
3-[1-(1h-indol-3-yl)-3-methylbut-2-en-1-yl]-7-(3-methylbut-2-en-1-yl)-1h-indole
1,8a-dimethyl-6-oxo-7-(propan-2-ylidene)-2,8-dihydro-1h-naphthalen-2-yl 6-methylocta-2,4-dienoate
(3s,4s)-3-[(1s)-2-[(1r,4as,5r,6r,8as)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]-1-hydroxyethyl]-4-hydroxyoxolan-2-one
(3r,5s,6r,7s,9r,11z,13r,14r)-14-ethyl-6,13-dihydroxy-3,5,7,9,13-pentamethyl-1-oxacyclotetradec-11-ene-2,4,10-trione
(8-hydroxy-8-isopropyl-5-methyl-4,4a,5,6,7,8a-hexahydro-3h-naphthalen-2-yl)methyl 3-phenylprop-2-enoate
16-acetyl-8,8,13,17-tetramethyl-7-oxatetracyclo[10.7.0.0³,⁹.0¹³,¹⁷]nonadeca-1(12),2,4-trien-6-one
(1r,2s,4ar,5r,8as)-5-hydroxy-2-isopropyl-4a,8-dimethyl-2,3,4,5,6,8a-hexahydro-1h-naphthalen-1-yl (2e)-3-phenylprop-2-enoate
(1r,2s,3r,6r,7s,9s,10s,11s,13r,14s)-11-isopropyl-3,7,10-trimethyl-15-oxapentacyclo[7.5.1.0²,⁶.0⁷,¹³.0¹⁰,¹⁴]pentadecane-6,9,11,13,14-pentol
2-[(2-{6,10-dimethylspiro[4.5]dec-6-en-2-yl}propan-2-yl)oxy]-6-methyloxane-3,4,5-triol
(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-5,6,10,10b-tetrahydroxy-3,4a,7,7,10a-pentamethyl-hexahydro-2h-naphtho[2,1-b]pyran-1-one
(1r,4s,6s,9r,10z,13s,14r,17s)-9-hydroperoxy-13-hydroxy-4,9,13,17-tetramethyl-5,15-dioxatricyclo[12.3.1.0⁴,⁶]octadec-10-en-16-one
3-[(3e)-4-(1h-indol-6-yl)-2-methylbut-3-en-2-yl]-7-(3-methylbut-2-en-1-yl)-1h-indole
3-[1-(1h-indol-7-yl)-3-methylbut-2-en-1-yl]-7-(3-methylbut-2-en-1-yl)-1h-indole
1,8a-dimethyl-6-oxo-7-(prop-1-en-2-yl)-1,2,7,8-tetrahydronaphthalen-2-yl 6-methylocta-2,4-dienoate
3,4,7,11-tetrahydroxy-4,12-dimethyl-8,15-dimethylidene-13-oxabicyclo[10.3.2]heptadecan-14-one
(1r,2s,3r,4s,7r,8s)-4-isopropyl-1,7-dimethyl-11-oxatricyclo[6.2.1.0²,⁷]undecan-3-yl (2e)-3-phenylprop-2-enoate
(1s,3r,6s,8s,10s,13r,14r,16r)-3,6,8,14,16-pentahydroxy-5,5,14-trimethyl-9-methylidenetricyclo[11.2.1.0¹,¹⁰]hexadecan-4-one
methyl 3-[2-ethenyl-7-hydroxy-6-(2-hydroxypropan-2-yl)-2,5,8a-trimethyl-hexahydro-1-benzopyran-5-yl]propanoate
5,5,14-trimethyl-9-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecane-3,4,6,7,13,16-hexol
(2s,3r,4s,5r,6r)-2-({2-[(2s,5s,10r)-6,10-dimethylspiro[4.5]dec-6-en-2-yl]propan-2-yl}oxy)-6-methyloxane-3,4,5-triol
2-isopropyl-4a-methyl-8-methylidene-octahydronaphthalen-1-yl 3-(4-hydroxyphenyl)prop-2-enoate
(1s,2s,4ar,8as)-2-isopropyl-4a-methyl-8-methylidene-octahydronaphthalen-1-yl (2z)-3-(4-hydroxyphenyl)prop-2-enoate
5,5,14-trimethyl-9-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecane-3,4,6,7,14,16-hexol
4-{9a,11a-dimethyl-7-oxo-1h,2h,3h,3ah,3bh,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}pent-2-enoic acid
(3r,6e)-3-ethenyl-1-(2-hydroxy-6-methylphenyl)-3,7,11-trimethyldodeca-6,10-diene-1,5-dione
(1r,4s,5r,9r,10s,11s,13s,14s,15s)-11,14,15-trihydroxy-14-(hydroxymethyl)-5,9-dimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylic acid
(1r,2r,3s,6s,7r,9s,10r,11s,13r,14s)-11-isopropyl-3,7,10-trimethyl-15-oxapentacyclo[7.5.1.0²,⁶.0⁷,¹³.0¹⁰,¹⁴]pentadecane-6,9,11,13,14-pentol
methyl 3-[(2r,4as,5s,6r,7r,8as)-2-ethenyl-7-hydroxy-6-(2-hydroxypropan-2-yl)-2,5,8a-trimethyl-hexahydro-1-benzopyran-5-yl]propanoate
(1r,3ar,4r,8as)-8a-hydroxy-1-isopropyl-3a,6-dimethyl-1,2,3,4,7,8-hexahydroazulen-4-yl (2e)-3-phenylprop-2-enoate
5,9,13-trihydroxy-6-(hydroxymethyl)-2,6-dimethyltetracyclo[10.3.1.0¹,¹⁰.0²,⁷]hexadecane-13-carboxylic acid
(1r,2r,3s,4s,5r,9s,10s,13r,14s)-2,3,14-trihydroxy-14-(hydroxymethyl)-5,9-dimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylic acid
1-hydroxy-1,4a-dimethyl-6-oxo-7-(propan-2-ylidene)-hexahydronaphthalen-2-yl 2,3-dihydroxy-2-methylbutanoate
1-[(1r,9r,12r,19r)-12-ethyl-6-methoxy-8,16-diazapentacyclo[10.6.1.0¹,⁹.0²,⁷.0¹⁶,¹⁹]nonadeca-2,4,6-trien-8-yl]propan-1-one
C23H32N2O2 (368.24636519999996)
(1r,4s,6s,9s,10z,13s,14r,17s)-9-hydroperoxy-13-hydroxy-4,9,13,17-tetramethyl-5,15-dioxatricyclo[12.3.1.0⁴,⁶]octadec-10-en-16-one
3-ethenyl-5,6,10,10b-tetrahydroxy-3,4a,7,7,10a-pentamethyl-hexahydro-2h-naphtho[2,1-b]pyran-1-one
(3s,4s)-3-[(1r)-2-[(1r,4as,5s,6r,8ar)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]-1-hydroxyethyl]-4-hydroxyoxolan-2-one
(9r,13r,16s,17r)-16-acetyl-8,8,13,17-tetramethyl-7-oxatetracyclo[10.7.0.0³,⁹.0¹³,¹⁷]nonadeca-1(12),2,4-trien-6-one
(1r,3s,4r,7r,8r,11r,12r)-3,8,11-trihydroxy-4,8,12-trimethyl-15-methylidene-13,18-dioxatricyclo[10.3.2.1⁴,⁷]octadecan-14-one
3,6,8,14,16-pentahydroxy-5,5,14-trimethyl-9-methylidenetricyclo[11.2.1.0¹,¹⁰]hexadecan-4-one
(1s,3r,4r,6r,8s,9s,10r,11r,15r,17s)-5,5,10,15-tetramethyl-7-oxapentacyclo[12.2.1.0¹,¹¹.0⁴,⁹.0⁶,⁸]heptadecane-3,4,10,15,17-pentol
(4r)-4-(acetyloxy)-5-hydroxy-5-undecanoylcyclopent-2-en-1-yl acetate
(1r,3r,4r,6r,8s,9s,10r,11r,14s,15r)-5,5,10,15-tetramethyl-7-oxapentacyclo[12.2.1.0¹,¹¹.0⁴,⁹.0⁶,⁸]heptadecane-3,4,10,14,15-pentol
[(4as,5r,8s,8ar)-8-hydroxy-8-isopropyl-5-methyl-4,4a,5,6,7,8a-hexahydro-3h-naphthalen-2-yl]methyl (2e)-3-phenylprop-2-enoate
(3s,4s)-3-[(1r)-2-[(1r,4as,5r,6r,8as)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]-1-hydroxyethyl]-4-hydroxyoxolan-2-one
(1r,4r,9r,10r,12r,13r,14s)-10,12,13,14-tetrahydroxy-14-(hydroxymethyl)-5,5,9-trimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-11-one
(1s,3r,4r,6r,7r,8s,9r,10r,13s,16r)-5,5,9,14-tetramethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadec-14-ene-3,4,6,7,9,16-hexol
(3ar,3bs,5ar,9as,9bs)-1-acetyl-3a,3b,6,6,9a-pentamethyl-3h,4h,5h,5ah,8h,9h,9bh-cyclopenta[a]phenanthrene-2,7-dione
1-{12-ethyl-6-methoxy-8,16-diazapentacyclo[10.6.1.0¹,⁹.0²,⁷.0¹⁶,¹⁹]nonadeca-2,4,6-trien-8-yl}propan-1-one
C23H32N2O2 (368.24636519999996)
8-formyl-2-isopropyl-4a-methyl-octahydro-1h-naphthalen-1-yl 3-phenylprop-2-enoate
4-hydroxy-7-isopropyl-1,4a-dimethyl-2,3,4,5,6,8a-hexahydronaphthalen-1-yl 3-phenylprop-2-enoate
(1s,2s,5r,6r,7r,9s,10s,12r,13r)-5,9,13-trihydroxy-6-(hydroxymethyl)-2,6-dimethyltetracyclo[10.3.1.0¹,¹⁰.0²,⁷]hexadecane-13-carboxylic acid
(1r,2s,4ar,8s,8as)-8-formyl-2-isopropyl-4a-methyl-octahydro-1h-naphthalen-1-yl (2e)-3-phenylprop-2-enoate
5,5,9-trimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecane-3,4,6,7,9,16-hexol
4-isopropyl-1,7-dimethyl-11-oxatricyclo[6.2.1.0²,⁷]undecan-3-yl 3-phenylprop-2-enoate
(3r,4s)-3-[(1r)-2-[(1r,4as,5r,6r,8as)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]-1-hydroxyethyl]-4-hydroxyoxolan-2-one
4-hydroxy-3-{1-hydroxy-2-[6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]ethyl}oxolan-2-one
10,12,13,14-tetrahydroxy-14-(hydroxymethyl)-5,5,9-trimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-11-one
2-[5-(carboxymethyl)-2-ethenyl-3-hydroxy-2,5,8a-trimethyl-hexahydro-1-benzopyran-6-yl]-2-methylpropanoic acid
(1r,3e,7e)-3,7,10,10-tetramethylcycloundeca-3,7-dien-1-yl (2e)-3-(4-hydroxyphenyl)prop-2-enoate
(1r,2r,4r,8s,9r,10s,13s,14s,16s)-2,8,16-trihydroxy-9,14-bis(hydroxymethyl)-5,5-dimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-15-one
2-hydroxy-9-(5-hydroxy-3-methylpent-3-en-1-yl)-1-(5-hydroxy-4-methylpent-3-en-1-yl)-5-methyl-6,8-dioxabicyclo[3.2.2]nonan-7-one
7-[6-(3-hydroperoxyoct-1-en-1-yl)-2,3-dioxabicyclo[2.2.1]heptan-5-yl]hept-5-enoic acid
(1r,3s,4r,7s,8s,11s,12r)-3,8,11-trihydroxy-4,8,12-trimethyl-15-methylidene-13,18-dioxatricyclo[10.3.2.1⁴,⁷]octadecan-14-one
4-hydroxy-1-[5-hydroxy-3-(hydroxymethyl)pent-3-en-1-yl]-1-(hydroxymethyl)-2,5-dimethyl-2,3,4,7,8,8a-hexahydroazulene-3a-carboxylic acid
(1r,3s,4r,7s,8r,11r,12r)-3,8,11-trihydroxy-4,8,12-trimethyl-15-methylidene-13,18-dioxatricyclo[10.3.2.1⁴,⁷]octadecan-14-one
(1s,3r,4s,7r,8r,11r,12s)-3,8,11-trihydroxy-4,8,12-trimethyl-15-methylidene-13,18-dioxatricyclo[10.3.2.1⁴,⁷]octadecan-14-one
(1r,2s,8ar)-1,8a-dimethyl-6-oxo-7-(prop-1-en-2-yl)-1,2,7,8-tetrahydronaphthalen-2-yl (2e,4e,6s)-6-methylocta-2,4-dienoate
(1r,2s,3s,4r,6s,8s,10s,13r,14r,16r)-5,5,14-trimethyl-9-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecane-2,3,4,6,14,16-hexol
(1s,3s,4as,8r,8ar)-8-hydroxy-3-isopropyl-5,8a-dimethyl-2,3,4,4a,7,8-hexahydro-1h-naphthalen-1-yl (2e)-3-phenylprop-2-enoate
2-[(2s,3r,4as,5r,6s,8as)-5-(carboxymethyl)-2-ethenyl-3-hydroxy-2,5,8a-trimethyl-hexahydro-1-benzopyran-6-yl]-2-methylpropanoic acid
[(4as,5r,8s,8ar)-8-hydroxy-8-isopropyl-5-methyl-4,4a,5,6,7,8a-hexahydro-3h-naphthalen-2-yl]methyl (2z)-3-phenylprop-2-enoate
(1s,3r,4s,7r,11r,12s)-3,4,7,11-tetrahydroxy-4,12-dimethyl-8,15-dimethylidene-13-oxabicyclo[10.3.2]heptadecan-14-one
(1r,2s,5r,9s)-2-hydroxy-9-[(3z)-5-hydroxy-3-methylpent-3-en-1-yl]-1-[(3z)-5-hydroxy-4-methylpent-3-en-1-yl]-5-methyl-6,8-dioxabicyclo[3.2.2]nonan-7-one
n,6,13-trimethyl-16-oxo-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-diene-7-carboximidic acid
C23H32N2O2 (368.24636519999996)
(1r,4s,6s,9s,10e,13s,14r,17s)-9-hydroperoxy-13-hydroxy-4,9,13,17-tetramethyl-5,15-dioxatricyclo[12.3.1.0⁴,⁶]octadec-10-en-16-one
7-{2-[7-methyl-5-(2-methylprop-1-en-1-yl)-1h,5h,6h-cyclopenta[f]indol-7-yl]ethenyl}-2,3-dihydro-1h-indole
(1r,2r,3s,4s,5r,9s,10s,13r,14r)-2,3,14-trihydroxy-14-(hydroxymethyl)-5,9-dimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylic acid
2,3,14-trihydroxy-14-(hydroxymethyl)-5,9-dimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylic acid
5-[(2h-chromen-7-yloxy)methyl]-1,5,6,8a-tetramethyl-hexahydro-1h-naphthalen-2-one
(1r,2r,3s,7r,8r,10s,12r,13r,16r)-2,7,8,10,12-pentahydroxy-2,6,6,12-tetramethyltetracyclo[8.5.1.0³,⁷.0¹³,¹⁶]hexadecan-5-one
(6r)-4-methoxy-6-[(2s,3s,4s,5e,7s,8r,9e)-2,4,8-trihydroxy-3,7,9-trimethylundeca-5,9-dien-1-yl]-5,6-dihydropyran-2-one
14-ethyl-6,13-dihydroxy-3,5,7,9,13-pentamethyl-1-oxacyclotetradec-11-ene-2,4,10-trione
5,5,9,14-tetramethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadec-14-ene-3,4,6,7,9,16-hexol
2,7,8,10,12-pentahydroxy-2,6,6,12-tetramethyltetracyclo[8.5.1.0³,⁷.0¹³,¹⁶]hexadecan-5-one
(11e)-14-ethyl-6,13-dihydroxy-3,5,7,9,13-pentamethyl-1-oxacyclotetradec-11-ene-2,4,10-trione
1-[7,9b-dimethyl-1-(2-phenylethoxy)-3h,3ah,5ah,6h,7h,8h,9h,9ah-naphtho[1,2-c]furan-1-yl]ethanone
5-hydroxy-4-{3-[(2s,3'r,5r,6's)-6'-(2-hydroxypropan-2-yl)-[2,3'-bioxan]-5-yl]propyl}-5h-furan-2-one
(1s,3r,4r,6r,7s,8r,10s,13r,14r,16s)-5,5,14-trimethyl-9-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecane-3,4,6,7,14,16-hexol
5,5,10,15-tetramethyl-7-oxapentacyclo[12.2.1.0¹,¹¹.0⁴,⁹.0⁶,⁸]heptadecane-3,4,10,15,17-pentol
[(1s,4as,6s,7r,7as)-6-hydroxy-7-methyl-1-[(3-methylbutanoyl)oxy]-1h,4ah,5h,6h,7h,7ah-cyclopenta[c]pyran-4-yl]methyl 3-methylbutanoate
(1s,3e,7e)-3,7,10,10-tetramethylcycloundeca-3,7-dien-1-yl (2e)-3-(4-hydroxyphenyl)prop-2-enoate
11,14,15-trihydroxy-14-(hydroxymethyl)-5,9-dimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylic acid
[(1s,4as,6r,7r,7as)-6-hydroxy-7-methyl-1-[(3-methylbutanoyl)oxy]-1h,4ah,5h,6h,7h,7ah-cyclopenta[c]pyran-4-yl]methyl 3-methylbutanoate
5,5,10,15-tetramethyl-7-oxapentacyclo[12.2.1.0¹,¹¹.0⁴,⁹.0⁶,⁸]heptadecane-3,4,10,14,15-pentol
2-(hepta-1,4-dien-1-yl)-17-hydroxy-15-oxabicyclo[12.2.2]octadeca-1(17),3,6,14(18)-tetraen-16-one
(1s,2r,5r,6r,7s,10r,12r,13r,14r)-13-(hydroxymethyl)-8-isopropyl-2,5-dimethyl-15-oxatetracyclo[10.2.1.0²,¹⁰.0⁵,⁹]pentadec-8-ene-1,6,7,14-tetrol
(1r,4r)-4-(acetyloxy)-5-hydroxy-5-undecanoylcyclopent-2-en-1-yl acetate
(1s)-3,7,10,10-tetramethylcycloundeca-3,7-dien-1-yl 3-(4-hydroxyphenyl)prop-2-enoate
(1r,2s,4as,5s,8ar)-5-hydroxy-2-isopropyl-4a-methyl-8-methylidene-octahydronaphthalen-1-yl (2e)-3-phenylprop-2-enoate
(3r,4s)-3-[(1r)-2-[(1r,4as,5s,6r,8ar)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]-1-hydroxyethyl]-4-hydroxyoxolan-2-one
(1s,2r,4ar,8ar)-1-hydroxy-1,4a-dimethyl-6-oxo-7-(propan-2-ylidene)-hexahydronaphthalen-2-yl (2s,3s)-2,3-dihydroxy-2-methylbutanoate
(1s,2r,5r,6s,7s,10r,12r,13r,14r)-13-(hydroxymethyl)-8-isopropyl-2,5-dimethyl-15-oxatetracyclo[10.2.1.0²,¹⁰.0⁵,⁹]pentadec-8-ene-1,6,7,14-tetrol
7-[(2r,3s,4s)-4-hydroxy-2-[(1e,3s)-3-hydroxyoct-1-en-1-yl]-6-oxooxan-3-yl]hept-5-enoic acid
5-hydroxy-4-{3-[6'-(2-hydroxypropan-2-yl)-[2,3'-bioxan]-5-yl]propyl}-5h-furan-2-one
(3r,4ar,5s,6s,10s,10ar,10bs)-3-ethenyl-5,6,10,10b-tetrahydroxy-3,4a,7,7,10a-pentamethyl-hexahydro-2h-naphtho[2,1-b]pyran-1-one
(1r,2s,5s,6s,9r,12s,13r)-n,6,13-trimethyl-16-oxo-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-diene-7-carboximidic acid
C23H32N2O2 (368.24636519999996)
[(1s,4as,6s,7r,7ar)-6-hydroxy-7-methyl-1-[(3-methylbutanoyl)oxy]-1h,4ah,5h,6h,7h,7ah-cyclopenta[c]pyran-4-yl]methyl 3-methylbutanoate
(2r,3z,6z)-2-[(1e,4z)-hepta-1,4-dien-1-yl]-17-hydroxy-15-oxabicyclo[12.2.2]octadeca-1(17),3,6,14(18)-tetraen-16-one
2-[(2r,4as,5r,6s,8as)-5-(carboxymethyl)-2,5,8a-trimethyl-2-[(2r)-oxiran-2-yl]-hexahydro-1-benzopyran-6-yl]-2-methylpropanoic acid
(1r,2s,7r,8ar)-1,8a-dimethyl-6-oxo-7-(prop-1-en-2-yl)-1,2,7,8-tetrahydronaphthalen-2-yl (2e,4e,6s)-6-methylocta-2,4-dienoate
(1s,3r,4r,6s,7r,8s,9r,10s,13s,16s)-5,5,9,14-tetramethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadec-14-ene-3,4,6,7,9,16-hexol
(1s,3r,4r,6r,8s,9s,10r,11s,14r,15r,17r)-5,5,10,15-tetramethyl-7-oxapentacyclo[12.2.1.0¹,¹¹.0⁴,⁹.0⁶,⁸]heptadecane-3,4,10,15,17-pentol
4-{2-[2-(1,2-dihydroxyethyl)oxiran-2-yl]-2-hydroxyethyl}-2-hydroxy-3,4,8,8a-tetramethyl-3,4a,5,6-tetrahydro-2h-naphthalen-1-one
6-{4,10-dihydroxy-3,5,8,9-tetramethyl-1,7-dioxaspiro[5.5]undecan-2-yl}hepta-2,4-dienoic acid
(1r,3s,4s,6r,8s,9s,10r,11s,14s,15s,17r)-5,5,10,15-tetramethyl-7-oxapentacyclo[12.2.1.0¹,¹¹.0⁴,⁹.0⁶,⁸]heptadecane-3,4,10,15,17-pentol
(1s,2r,5s,6s,7r,8s)-5-isopropyl-2,8-dimethyltricyclo[4.4.0.0²,⁸]decan-7-yl (2e)-3-(4-hydroxyphenyl)prop-2-enoate
2-[(2r,4as,5r,6s,8as)-5-(carboxymethyl)-2,5,8a-trimethyl-2-[(2s)-oxiran-2-yl]-hexahydro-1-benzopyran-6-yl]-2-methylpropanoic acid
(1r,3r,4r,6r,7s,8r,10s,13r,14s,16r)-5,5,14-trimethyl-9-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecane-3,4,6,7,13,16-hexol
(3r,4s)-3-[(1s)-2-[(1r,4as,5r,6r,8ar)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]-1-hydroxyethyl]-4-hydroxyoxolan-2-one
(1r,2r,3ar,4r,8ar)-4-hydroxy-1-[(3z)-5-hydroxy-3-(hydroxymethyl)pent-3-en-1-yl]-1-(hydroxymethyl)-2,5-dimethyl-2,3,4,7,8,8a-hexahydroazulene-3a-carboxylic acid
(1r,3r,4r,6r,7r,8s,9r,10r,16s)-5,5,9,14-tetramethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadec-14-ene-3,4,6,7,9,16-hexol
(1s,2s,4ar,8as)-2-isopropyl-4a-methyl-8-methylidene-octahydronaphthalen-1-yl 3-(4-hydroxyphenyl)prop-2-enoate
5-isopropyl-2,8-dimethyltricyclo[4.4.0.0²,⁸]decan-7-yl 3-(4-hydroxyphenyl)prop-2-enoate
(1r,4s,6s,9r,10e,13s,14r,17s)-9-hydroperoxy-13-hydroxy-4,9,13,17-tetramethyl-5,15-dioxatricyclo[12.3.1.0⁴,⁶]octadec-10-en-16-one
10-hydroperoxy-13-hydroxy-4,13,17-trimethyl-9-methylidene-5,15-dioxatricyclo[12.3.1.0⁴,⁶]octadecan-16-one
(1r,2s,5s,6s,12s,13s)-n,6,13-trimethyl-16-oxo-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-diene-7-carboximidic acid
C23H32N2O2 (368.24636519999996)